Comparative toxicity of the hematinic MDL 80,478 — Effects on the liver and adrenal cortex of the dog, rat and monkey

Yarrington, J. T.; Huffman, Kenneth W.; Leeson, Gerald A.; Sprinkle, D. Jean; Loudy, David E.; Hampton, Caryn; Wright, George J.; Gibson, John P.

doi:10.1016/s0272-0590(83)80061-x

Cited by 15 publications

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Toxicology and antitumour activity of ferrocenylamines and platinum derivatives

Mason

McGrouther

Ranatunge-Bandarage

et al. 1999

Appl. Organometal. Chem.

View full text Add to dashboard Cite

Toxicity, antitumour, platinum distribution, hepatotoxicity and histology data are presented for a series of ferrocenylamines: [(η‐C5H4(CH2)nNH2)FeCp] (n = 0,1) (1,2); [(η‐C5H4CH2NHPh)FeCp] (3); [(η‐C5H4CH2NMe2)FeCp] (4); {[η‐C5H4CH(Me)NMe2]FeCp} (5); [η‐C5H4CH2NMe2)2Fe] (6); {[1,2η‐C5H3(CHMeNMe2)(PPh2)]FeCp} (7); {[1,2η‐C5H3(CHMeNMe2)(PPh2)]Fe[η‐C5H4PPh2]} (8); and their complexes cis‐PtCl2L2 (9); trans ‐ Pt(L)(dmso)X2 (10); [σ ‐ (L)Pt(dmso)X] (11,12) {σ‐(L)[Pt(dmso)X]2} (13); [σ‐(L)PtP(OPh)3Cl] (14) (L = ferrocenylamine). The toxicity order is 1–3 ≫ 4–8 for the ferrocenylamines; the lower toxicity of tertiary amines may be due to protonation in vivo. Pt(II) complexes all show increased toxicity over the ligand. Liver, not kidney, damage is the norm from i.p. injection of 1–14 and detailed platinum distribution, blood serum and histology studies with 9 and 11 show that the platinum distribution does not correlate with liver dysfunction. Complexes 9–14, but not 1–8, were active against P‐388 mouse leukaemia tumour and cisplatin‐resistant sarcoma, but inactive against L‐1210 mouse leukaemia and B‐16 melanoma. Copyright © 1999 John Wiley & Sons, Ltd.

show abstract

Toxicology and antitumour activity of ferrocenylamines and platinum derivatives

Mason

McGrouther

Ranatunge-Bandarage

et al. 1999

Appl. Organometal. Chem.

View full text Add to dashboard Cite

show abstract

Chemically Induced Adrenocortical Degenerative Lesions

Yarrington

Reindel²

1996

Monographs on Pathology of Laboratory Animals

View full text Add to dashboard Cite

Ferrocenes as potential anticancer drugs. Facts and hypotheses

et al. 2014

View full text Add to dashboard Cite

We analyzed the research data on antitumor effects of a wide range of ferrocene compounds and discussed possible mechanisms of their bioactivities. Current trends in the study of antican cer effects of ferrocene derivatives were considered. Promising ways in the design of low toxicity anticancer ferrocene based drugs of new generation were outlined. * Dedicated to the 60th anniversary of the A. N. Nesmeyanov Institute of Organoelement Compounds of the Russian Academy of Sciences (INEOS RAS). The review was written on the initiative and with the active participation of Yu. S. Nekrasov who served with good faith and fidelity for INEOS RAS for more than 40 years. † Deceased.

show abstract

Comparative toxicity of the hematinic MDL 80,478 — Effects on the liver and adrenal cortex of the dog, rat and monkey

Cited by 15 publications

References 13 publications

Toxicology and antitumour activity of ferrocenylamines and platinum derivatives

Toxicology and antitumour activity of ferrocenylamines and platinum derivatives

Chemically Induced Adrenocortical Degenerative Lesions

Ferrocenes as potential anticancer drugs. Facts and hypotheses

Contact Info

Product

Resources

About